Towards Healthcare
Chronic Lower Back Pain Market Rises by 9.52% CAGR till 2034

Chronic Lower Back Pain Market Size, Implications and Patient-Centered Approaches

According to market projections, the global chronic lower back pain market, valued at USD 2.69 billion in 2024, is anticipated to reach USD 6.69 billion by 2034, growing at a CAGR of 9.52% over the next decade. The increasing geriatric population with arthritis is one of the leading causes of chronic lower back pain, which is driving the market’s growth.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Chronic Lower Back Pain Market Assessment

  • Overview
  • Global Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Non-steroidal Anti-inflammatory Drugs
    • Antidepressants
    • Analgesic
    • Opioids
    • Others
  • Global Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Topical
    • Others
  • Global Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail & Online Pharmacies
  • Global Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Region (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa

North America Chronic Lower Back Pain Market Assessment

  • Overview
  • North America Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Non-steroidal Anti-inflammatory Drugs
    • Antidepressants
    • Analgesic
    • Opioids
    • Others
  • North America Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Topical
    • Others
  • North America Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail & Online Pharmacies

Europe Chronic Lower Back Pain Market Assessment

  • Overview
  • Europe Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Non-steroidal Anti-inflammatory Drugs
    • Antidepressants
    • Analgesic
    • Opioids
    • Others
  • Europe Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Topical
    • Others
  • Europe Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail & Online Pharmacies

Asia Pacific Chronic Lower Back Pain Market Assessment

  • Overview
  • Asia Pacific Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Non-steroidal Anti-inflammatory Drugs
    • Antidepressants
    • Analgesic
    • Opioids
    • Others
  • Asia Pacific Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Topical
    • Others
  • Asia Pacific Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail & Online Pharmacies

Latin America Chronic Lower Back Pain Market Assessment

  • Overview
  • Latin America Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Non-steroidal Anti-inflammatory Drugs
    • Antidepressants
    • Analgesic
    • Opioids
    • Others
  • Latin America Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Topical
    • Others
  • Latin America Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail & Online Pharmacies

Middle East & Africa Chronic Lower Back Pain Market Assessment

  • Overview
  • Middle East & Africa Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Non-steroidal Anti-inflammatory Drugs
    • Antidepressants
    • Analgesic
    • Opioids
    • Others
  • Middle East & Africa Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Route of Administration (2021 – 2033)
    • Oral
    • Topical
    • Others
  • Middle East & Africa Chronic Lower Back Pain Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail & Online Pharmacies

Company Profiles

  • SpineThera Inc. (U.S.)
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Pfizer Inc (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Johnson & Johnson Private Limited (U.S.)
  • Medtronic (Ireland)
  • Endo Pharmaceuticals Inc. (Ireland)
  • Sanofi (France)
  • Merck & Co Inc. (U.S.)
  • Koninklijke Philips N.V. (Netherlands)
  • Vertebral Technologies, Inc. (U.S.)
  • Boston Scientific Corporation (U.S.)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • Astellas Pharma Inc. (Japan)
  • CELGENE CORPORATION (U.S.)

Conclusion & Recommendations

  • Insight Code: 5156
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: May 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

Physical therapy, home exercise, meditation, proper diet, modification of lifestyle, use of injectables and pharmacologic treatments.

Spine X-ray, MRI, CT scan, electromyography and other tests depending on the cause of the pain.

FDA, World Health Organization, Centers for Disease Control and Prevention, American Association of Neurological Surgeons, National Institute of Health and Bone and Joint Canada.